Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Structure-based optimization of a potent class of arylamide FMS inhibitors.

Meegalla SK, Wall MJ, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Illig CR.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3632-7. doi: 10.1016/j.bmcl.2008.04.059. Epub 2008 Apr 26.

PMID:
18495479
2.

Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.

Illig CR, Chen J, Wall MJ, Wilson KJ, Ballentine SK, Rudolph MJ, DesJarlais RL, Chen Y, Schubert C, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1642-8. doi: 10.1016/j.bmcl.2008.01.059. Epub 2008 Jan 19.

PMID:
18242992
3.

Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.

Patch RJ, Brandt BM, Asgari D, Baindur N, Chadha NK, Georgiadis T, Cheung WS, Petrounia IP, Donatelli RR, Chaikin MA, Player MR.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6070-4. Epub 2007 Sep 19.

PMID:
17904845
4.

Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.

Burns CJ, Harte MF, Bu X, Fantino E, Giarrusso M, Joffe M, Kurek M, Legge FS, Razzino P, Su S, Treutlein H, Wan SS, Zeng J, Wilks AF.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1206-9. doi: 10.1016/j.bmcl.2008.12.073. Epub 2008 Dec 25.

PMID:
19128971
5.

Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists.

Lippa B, Morris J, Corbett M, Kwan TA, Noe MC, Snow SL, Gant TG, Mangiaracina M, Coffey HA, Foster B, Knauth EA, Wessel MD.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3444-8. Epub 2006 Apr 24.

PMID:
16632359
6.

Synthesis of novel anilinoquinolines as c-fms inhibitors.

Smalley TL Jr, Chamberlain SD, Mills WY, Musso DL, Randhawa SA, Ray JA, Samano V, Frick L.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6257-60. Epub 2007 Sep 7.

PMID:
17870531
7.

Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.

Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3925-9. doi: 10.1016/j.bmcl.2010.05.013. Epub 2010 May 12.

PMID:
20570147
8.

Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.

Huang H, Hutta DA, Rinker JM, Hu H, Parsons WH, Schubert C, DesJarlais RL, Crysler CS, Chaikin MA, Donatelli RR, Chen Y, Cheng D, Zhou Z, Yurkow E, Manthey CL, Player MR.

J Med Chem. 2009 Feb 26;52(4):1081-99. doi: 10.1021/jm801406h.

PMID:
19193011
9.

Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.

Taylor SJ, Soleymanzadeh F, Eldrup AB, Farrow NA, Muegge I, Kukulka A, Kabcenell AK, De Lombaert S.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. doi: 10.1016/j.bmcl.2009.08.074. Epub 2009 Aug 26.

PMID:
19758802
10.

Design, synthesis and evaluation of potent thymidylate synthase X inhibitors.

Esra Onen F, Boum Y, Jacquement C, Spanedda MV, Jaber N, Scherman D, Myllykallio H, Herscovici J.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3628-31. doi: 10.1016/j.bmcl.2008.04.080. Epub 2008 May 6.

PMID:
18513963
11.

'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5456-9. doi: 10.1016/j.bmcl.2008.09.028. Epub 2008 Sep 11.

PMID:
18835164
12.

Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).

Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.

J Med Chem. 2011 Nov 24;54(22):7860-83. doi: 10.1021/jm200900q. Epub 2011 Oct 31.

PMID:
22039836
13.

Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.

Cogan DA, Aungst R, Breinlinger EC, Fadra T, Goldberg DR, Hao MH, Kroe R, Moss N, Pargellis C, Qian KC, Swinamer AD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3251-5. doi: 10.1016/j.bmcl.2008.04.043. Epub 2008 Apr 25.

PMID:
18462940
14.

Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.

Matter H, Scheiper B, Steinhagen H, Böcskei Z, Fleury V, McCort G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5487-92. doi: 10.1016/j.bmcl.2011.06.112. Epub 2011 Jul 2.

PMID:
21840215
15.

Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.

Scheiper B, Matter H, Steinhagen H, Böcskei Z, Fleury V, McCort G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5480-6. doi: 10.1016/j.bmcl.2011.06.114. Epub 2011 Jul 6.

PMID:
21840218
16.

Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening.

Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ.

ChemMedChem. 2008 Jun;3(6):877-80. doi: 10.1002/cmdc.200700348. No abstract available.

PMID:
18236492
17.

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.

Illig CR, Manthey CL, Meegalla SK, Wall MJ, Chen J, Wilson KJ, DesJarlais RL, Ballentine SK, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6363-9. doi: 10.1016/j.bmcl.2013.09.061. Epub 2013 Oct 1.

PMID:
24138939
18.

Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.

Vaz RJ, Gao Z, Pribish J, Chen X, Levell J, Davis L, Albert E, Brollo M, Ugolini A, Cramer DM, Cairns J, Sides K, Liu F, Kwong J, Kang J, Rebello S, Elliot M, Lim H, Chellaraj V, Singleton RW, Li Y.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6053-6.

PMID:
15546728
19.

Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors.

Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3965-8. doi: 10.1016/j.bmcl.2010.04.134. Epub 2010 May 4.

PMID:
20537533
20.

Design of more potent squalene synthase inhibitors with multiple activities.

Kourounakis AP, Matralis AN, Nikitakis A.

Bioorg Med Chem. 2010 Nov 1;18(21):7402-12. doi: 10.1016/j.bmc.2010.09.008. Epub 2010 Sep 7.

PMID:
20888243

Supplemental Content

Support Center